Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.

Background: Glycoprotein IIb/IIIa receptor antagonists have been shown to have an impact on the outcomes of death/myocardial infarction (MI) in patients undergoing percutaneous coronary intervention. At our institution, tirofiban has largely replaced abciximab in an attempt to decrease costs.

Objective: To assess the impact of this change on patient outcomes in the absence of head-to-head trials.